Summary | |
---|---|
Symbol | BRD7 |
Name | bromodomain containing 7 |
Aliases | CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Isoform 2: Nucleus. |
Domain |
PF00439 Bromodomain PF12024 Domain of unknown function (DUF3512) |
Function |
Acts both as coactivator and as corepressor. May play a role in chromatin remodeling. Activator of the Wnt signaling pathway in a DVL1-dependent manner by negatively regulating the GSK3B phosphotransferase activity. Induces dephosphorylation of GSK3B at 'Tyr-216'. Down-regulates TRIM24-mediated activation of transcriptional activation by AR (By similarity). Transcriptional corepressor that down-regulates the expression of target genes. Binds to target promoters, leading to increased histone H3 acetylation at 'Lys-9' (H3K9ac). Binds to the ESR1 promoter. Recruits BRCA1 and POU2F1 to the ESR1 promoter. Coactivator for TP53-mediated activation of transcription of a set of target genes. Required for TP53-mediated cell-cycle arrest in response to oncogene activation. Promotes acetylation of TP53 at 'Lys-382', and thereby promotes efficient recruitment of TP53 to target promoters. Inhibits cell cycle progression from G1 to S phase. |
Biological Process |
GO:0000082 G1/S transition of mitotic cell cycle GO:0006473 protein acetylation GO:0006475 internal protein amino acid acetylation GO:0007346 regulation of mitotic cell cycle GO:0010948 negative regulation of cell cycle process GO:0016055 Wnt signaling pathway GO:0016570 histone modification GO:0016573 histone acetylation GO:0018205 peptidyl-lysine modification GO:0018393 internal peptidyl-lysine acetylation GO:0018394 peptidyl-lysine acetylation GO:0031056 regulation of histone modification GO:0031058 positive regulation of histone modification GO:0035065 regulation of histone acetylation GO:0035066 positive regulation of histone acetylation GO:0043543 protein acylation GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044843 cell cycle G1/S phase transition GO:0045786 negative regulation of cell cycle GO:0045930 negative regulation of mitotic cell cycle GO:0072331 signal transduction by p53 class mediator GO:0198738 cell-cell signaling by wnt GO:1901796 regulation of signal transduction by p53 class mediator GO:1901983 regulation of protein acetylation GO:1901985 positive regulation of protein acetylation GO:1901987 regulation of cell cycle phase transition GO:1901988 negative regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901991 negative regulation of mitotic cell cycle phase transition GO:1902275 regulation of chromatin organization GO:1902806 regulation of cell cycle G1/S phase transition GO:1902807 negative regulation of cell cycle G1/S phase transition GO:1905269 positive regulation of chromatin organization GO:2000045 regulation of G1/S transition of mitotic cell cycle GO:2000134 negative regulation of G1/S transition of mitotic cell cycle GO:2000756 regulation of peptidyl-lysine acetylation GO:2000758 positive regulation of peptidyl-lysine acetylation |
Molecular Function |
GO:0002039 p53 binding GO:0003713 transcription coactivator activity GO:0003714 transcription corepressor activity GO:0008134 transcription factor binding GO:0042393 histone binding GO:0070577 lysine-acetylated histone binding |
Cellular Component |
GO:0070603 SWI/SNF superfamily-type complex GO:0090544 BAF-type complex |
KEGG | - |
Reactome |
R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-5633007: Regulation of TP53 Activity R-HSA-6804758: Regulation of TP53 Activity through Acetylation R-HSA-3700989: Transcriptional Regulation by TP53 |
Summary | |
---|---|
Symbol | BRD7 |
Name | bromodomain containing 7 |
Aliases | CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between BRD7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | BRD7 |
Name | bromodomain containing 7 |
Aliases | CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of BRD7 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | BRD7 |
Name | bromodomain containing 7 |
Aliases | CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of BRD7 in various data sets.
|
Points in the above scatter plot represent the mutation difference of BRD7 in various data sets.
|
Summary | |
---|---|
Symbol | BRD7 |
Name | bromodomain containing 7 |
Aliases | CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BRD7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | BRD7 |
Name | bromodomain containing 7 |
Aliases | CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BRD7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BRD7. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | BRD7 |
Name | bromodomain containing 7 |
Aliases | CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BRD7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | BRD7 |
Name | bromodomain containing 7 |
Aliases | CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of BRD7 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | BRD7 |
Name | bromodomain containing 7 |
Aliases | CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between BRD7 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | BRD7 |
Name | bromodomain containing 7 |
Aliases | CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ...... |
Chromosomal Location | 16q12.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting BRD7 collected from DrugBank database. |
There is no record. |